Novel Treatment Combinations in Development for AML: The Role of Hypomethylating Agents

Novel Treatment Combinations in Development for AML: The Role of Hypomethylating Agents

MediComOncology

2 years
181 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Presented by Ehab Atallah, MD. There is a significant unmet need in existing treatment paradigms for patients with acute myeloid leukemia (AML) due to poor survival and intolerability to cytotoxic chemotherapy, especially for a generally older patient population. Hypomethylating agents (HMAs) have demonstrated a benefit in patients with AML, especially those who require less aggressive therapy, but there is a need for improved efficacy and survival outcomes. In this activity, participants will learn about HMAs in existing treatment paradigms, as well as the investigational landscape of novel therapies in combination with HMAs, and their potential impact on treatment outcomes for patients with AML. CE credit available at www.managingAML.com (expires 10/30/18).
Up Next Autoplay